Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
Achievement of glycemic control is the major therapeutic aim to prevent or delay the onset and progression of diabetes related complications. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. The aim for insulin therapy is to...
Saved in:
| Main Authors: | Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2014-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021-07-01) -
Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01) -
Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials
by: S. V. Nedogoda, et al.
Published: (2023-01-01) -
Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis
by: Saaed Abunada, et al.
Published: (2025-07-01) -
Modern basal insulins: an ongoing story or the start of a new era?
by: Ivan Ivanovich Dedov
Published: (2015-12-01)